B.C. Selects THC BioMed as “Exclusive to B.C.” Cannabis Provider

THC.CSE THCBF- OTC TFHC.F

VANCOUVER, May 9, 2019 /CNW/ – THC BioMed Intl Ltd. (“THC”, “THC BioMed” or the “Company”) (CSE: THC) THC BioMed is pleased to report that it has entered into an agreement with the BC Liquor Distribution Branch (“BCLDB”) to supply a number of its products exclusively to British Columbia.

 

The agreement was entered into after the BC Liquor Distribution Branch (BCLDB) met with THC BioMed management and toured THC’s flagship facility in Kelowna B.C.

 

The BCLDB will provide purchase orders to THC BioMed for the product quantities listed in the appendix to the agreement three months in advance of the available supply month.

 

THC BioMed Ltd. has committed to:

 

  • Supplying all produced dried flower product intended for the non-medical market, exclusively to the BCLDB until December 2019;
  • Maintaining Wholesale Cost incl. Excise as listed in the appendix to the Agreement until December 2019;
  • and Supplying the product as per the quantities and schedule listed in the appendix to the Agreement.

 

THC BioMed has agreed to exclusively supply the BCLDB with the following flower strains in 3.5-gram and 7-gram formats until December 2019:

 

  • THC Sativa LANDRACE
  • THC Indica LANDRACE
  • THC Hybrid LANDRACE
  • THC CBD Indica LANDRACE
  • Atomical Haze
  • West Coast Dream
  • Original Cheese
  • Jacky White

 

THC BioMed will continue to supply all provinces with its best-selling pre-rolls as well as THC Kiss when the regulations permit.

 

“We are proud that our products will be featured in our home province of BC. We continue to strive to produce cannabis products that are pure, clean and potent. We also look forward to launching THC Kiss, a pure organically produced cannabis beverage, when regulations permit” commented John Miller, CEO and president of THC BioMed.

 

THC BioMed continues to work vigorously towards securing supply agreements with various provincial governments.

 

AboutTHC BioMed

THC BioMed is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC BioMed is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry.

 

Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.

 

Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com

 

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that: (a) the parties will do as they promise under the Agreement; (b) THC will continue to supply all provinces with its best-selling pre-rolls as well as THC Kiss when the regulations permit, (c) the regulations will someday permit THC Kiss to be sold, (d) THC will produce cannabis products that are pure, clean and potent, (e) THC will launch THC Kiss and (f) THC continues to work vigorously towards securing supply agreements with various provincial governments. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

SOURCE THC BioMed

 

 

 

 

 

 

 

.